4//SEC Filing
Hineline Lawrence J. 4
Accession 0000950170-24-029582
CIK 0001567514other
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 8:33 PM ET
Size
24.0 KB
Accession
0000950170-24-029582
Insider Transaction Report
Form 4
Hineline Lawrence J.
VP of Finance, CFO & Secretary
Transactions
- Sale
Common Stock
2024-03-07$66.93/sh−6,618$442,943→ 0 total - Sale
Common Stock
2024-03-11$65.28/sh−4,453$290,692→ 1,129 total - Sale
Common Stock
2024-03-07$66.26/sh−6,514$431,618→ 6,618 total - Exercise/Conversion
Common Stock
2024-03-10+5,582→ 5,582 total - Sale
Common Stock
2024-03-11$66.54/sh−1,100$73,194→ 29 total - Exercise/Conversion
Common Stock
2024-03-10$56.73/sh+4,539$257,497→ 4,539 total - Sale
Common Stock
2024-03-11$67.32/sh−29$1,952→ 0 total - Sale
Common Stock
2024-03-11$66.47/sh−4,475$297,453→ 64 total - Sale
Common Stock
2024-03-11$67.12/sh−64$4,296→ 0 total - Exercise/Conversion
Restricted Stock Units
2024-03-10−5,582→ 5,582 total→ Common Stock (5,582 underlying) - Exercise/Conversion
Stock Option (right to purchase)
2024-03-10−4,539→ 4,539 totalExercise: $56.73Exp: 2032-03-09→ Common Stock (4,539 underlying)
Footnotes (12)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
- [F10]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F11]On March 10, 2022, the reporting person was granted 16,746 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- [F12]On March 10, 2022, the reporting person was granted options to purchase 13,616 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.8115 to $66.8069, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.81 to $67.145, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]Restricted stock units convert into common stock on a one-for-one basis.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.05 to $65.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.13 to $66.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F7]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.96 to $66.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.0012 to $67.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Documents
Issuer
Intra-Cellular Therapies, Inc.
CIK 0001567514
Entity typeother
Related Parties
1- filerCIK 0001585697
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 8:33 PM ET
- Size
- 24.0 KB